New hope for patients out of treatment options
NCT ID NCT04876456
Summary
This study is testing whether the drug cabozantinib can help control advanced germ cell tumors that have stopped responding to standard chemotherapy. It will involve about 50 adults whose cancer has progressed despite previous treatments. Participants will take the oral medication daily until their cancer worsens or side effects become too severe, with doctors monitoring tumor response and safety closely.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
Conditions
Explore the condition pages connected to this study.